View Clinical Trial (Medical Research Study)
The Importance of Periostin in Periodontal Health and Disease
| City: |
|
Ann Arbor |
| State: |
|
Michigan |
| Zip Code: |
|
48106 |
| Conditions: |
|
Periodontal Disease - Healthy Patients |
| Purpose: |
|
The goal of this study is to determine the clinical importance of Periostin in oral health
and disease. The long-term goal will be to develop practical applications for the diagnosis,
treatment, prevention and cure of human periodontal diseases.
|
| Study Summary: |
|
It is hypothesized that Periostin levels are decreased during periodontal diseases, thereby,
elevating the hosts' susceptibility to periodontal breakdown. The specific aims are the
following; To determine if Periostin is a biomarker of periodontal disease, and To evaluate
Periostin in periodontal tissue healing and homeostasis by harvesting healthy or diseased
tissue from 22 patients requiring periodontal surgery.
|
| Criteria: |
|
Inclusion Criteria:
Inclusion criteria for diseased subjects:
- Diagnosis of generalized chronic or aggressive periodontitis
- At least four periodontal sites with probing depth (PD) ≥6 mm, evidence of clinical
attachment loss (CAL), and bleeding on probing (BOP). Inclusion criteria for healthy
individuals will include PD <4 mm, no evidence of attachment loss, and <10% of sites
with BOP
- Need an open flap procedure
Inclusion criteria for non-diseased subjects:
- Subjects requiring a gingivectomy or crown lengthening procedure
Exclusion Criteria:
- History of alcoholism or drug abuse
- Medical conditions that may affect the outcome such as autoimmune diseases, diabetes,
immunocompromised subjects, neurologic or psychiatric disorders, systemic infections,
etc.
- Chronic medications known to affect the periodontal status (calcium antagonists,
anticonvulsives, immunosuppressives, anti-inflammatory medications, Depo-Provera
contraceptive injection users, new oral contraceptives users within 3 months of
baseline or subjects that are planning on, starting oral contraceptives during the
study.
- Antibiotic therapy within 3 months of the baseline visit, and/or antibiotic therapy
needed for infective endocarditis prophylaxis.
- Current use or quit smoking less than one year ago with a pack-year history of more
than or equal to 10.
- Untreated cavities
|
| NCT ID: |
|
NCT01180920 |
| Primary Contact: |
|
Principal Investigator
Hector Rios, MS, DDS
University of Michigan
Lea M Franco, MS, BS
Phone: (734) 998 - 6721
Email: mcohrclinicalresearch@umich.edu
|
| Backup Contact: |
|
Email: mcohrclinicalresearch@umich.edu
Anna M Galloro, BS, MT
Phone: (734) 998 - 6721
|
| Location Contact: |
|
Ann Arbor, Michigan 48106
United States
There is no listed contact information for this specific location.
Site Status: Recruiting |
| Data Source: |
|
ClinicalTrials.gov |
| Date Processed: |
|
May 17, 2013 |
| Modifications to this listing: |
|
Only selected fields are shown, please use the link
below to view all information about this clinical trial. |
|
Click to view Full Listing
|